RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026 FDA selects FT819 into the CDRP (CMC Development and Readiness Pilot) program enabling early and enhanced communication with the FDA to ensure CMC readiness for accelerated clinical timelines Clinical data presented at Pediatric Rheumatology Symposium 2026 and Congress of Clinical Rheumatology – East 2026 highlights safety and efficacy of single dose of FT819 with reduced conditioning in SLE Preclinical data presented at the American Association for Cancer Research 2026 demonstrates the unique ability of FT839 for comprehensive targeting of hematological malignancies and autoimmune diseases without the use of conditioning...

Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures FORT LAUDERDALE, Fla., May 13, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026. First Quarter 2026 OverviewRevenue increased 116.8% to $11.1 million from $5.1 million in the first quarter of 2025. Gross margin expanded to 48.0% from 21.2% in the first quarter of 2025. Gross profit rose 390.0% to $5.3...

CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY‑813 preclinical data on June 8, 2026 On track to advance CNTY‑308, Century’s CD19‑targeted CAR‑iT cell therapy, into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results...

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) perspectives on May 19, 2026 at 4:30 pm ET Interim safety and durability data from STARBORN-1 trial of TARA-002 in LMs to be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in May Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Presenting updated 12-month data from Phase 2 ADVANCED-2 trial of TARA-002 in patients with high-grade, BCG-Naïve non-muscle invasive bladder cancer (NMIBC) at the American Urological Association (AUA) Annual...

BALLERUP, Denmark, May 13, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the first quarter of 2026. Recent Financial HighlightsQ1 2026 revenue of $4.1 million compared to $4.6 million in Q1 2025. Q1 2026 net loss of $(2.7) million compared to $(2.4) million in Q1 2025. Q1 2026 Adjusted EBITDA of $(1.5) million compared to $(1.4) million in Q1 2025. Ending cash balance of $2.7 million on March 31, 2026.OutlookThe Company is reiterating its expectation for FY 2026 revenue between $23 million and $27 million, which would represent an increase of 39% to 64% over FY 2025.Recent Operational HighlightsElevated Commercial Pool activity with...

BROOKFIELD, Conn., May 13, 2026 (GLOBE NEWSWIRE) — Photronics, Inc. (Nasdaq: PLAB), a worldwide leader in photomask technologies and solutions, is scheduled to announce financial results for the second quarter of fiscal 2026 on Thursday, May 28, 2026, before the market opens. Photronics will host a public conference call the same day at 8:30 a.m. Eastern time. During the call, company management will respond to questions concerning, but not limited to, the company’s financial performance, business conditions, and industry outlook. Some responses may contain information not previously disclosed. The call will be broadcast live and on-demand on the Events and Presentations link on the Photronics website. Analysts and investors who wish to participate in the Q&A portion of the call should click here: Conference Registration....

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) — Swarmer, Inc (“Swarmer” or the “Company”) (Nasdaq: SWMR), a drone autonomy software company which has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today announced financial results for the quarter ended March 31, 2026 (“Q1 2026”), and discussed recent business developments. Management CommentarySwarmer President & U.S. CEO Alex Fink stated: “The first quarter of 2026 represented an important step forward for Swarmer as we completed our initial public offering, strengthened our leadership team and continued to expand our presence within the autonomous systems ecosystem. These milestones support our ability to pursue a rapidly expanding market, as demand for autonomous and collaborative unmanned systems continues to accelerate amid rising deployment...

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2026, which ended March 31, 2026. Financial Highlights & Recent DevelopmentsResearch and development expense was $554 thousand, a decline of 28% from the third quarter of fiscal year 2026 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect TRACER 1000 product lines. Through March 31, 2026, the Company has deployed the TRACER 1000 trace detection system in approximately 37 locations in 16 countries across the United States, Europe and Asia.“During the third quarter of fiscal year 2026, we remained focused on disciplined execution, achieving targeted cost-efficiency initiatives while...

Total Revenues of $48.5 million, at Top End of Guidance Range Trailing Twelve-Month Impressions Up Approximately 12% Year Over Year, Driven by Continued Screen-to-Digital Shift AIC Revenues Increased Approximately 103% Year Over Year Delivered Positive Operating Cash Flow for Tenth Consecutive Quarter Strong Customer Response and Growing Atlas MATRIX Backlog Reinforce Expansion of Digital Production at Scale Enters Second Quarter with Strengthening Momentum, Improved Visibility and Continued AIC Transition ROSH-HA`AYIN, Israel, May 13, 2026 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a global leader in sustainable, on-demand, digital fashion and textile production, today reported financial results for the first quarter ended March 31, 2026. The results reflect the Company’s continued progress...

– Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer –  – First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 – – Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia – – Announced Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Injury Repair – – U.S. Department of Defense funding for procurement of bioengineered blood vessels – – Major milestone upcoming: Top-line interim results from V012 Phase 3 study in hemodialysis access – -Conference call today at 8:00 am ET – DURHAM, N.C., May 13, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc....